Table 2.
Demographic in 71 mUC patients treated with palliatve radiation during follow-up.
| palliative radiation before pembro | concurrent palliative radiation with pembro | ||
|---|---|---|---|
| variables | (n = 71) | (n = 32) | (n = 39) |
| palliative radiation total dose (Gy) median [range] | 30 [8–64] | 37.5 [20–64] | 30 [8–60] |
| palliative radiation fraction: median [range] | 10 [1–30] | 14.5 [4–29] | 10 [1–30] |
| palliative radiation site (%) | |||
| bone | 26 (36.7) | 13(32.5) | 13 (32.5) |
| lymph nude | 20 (28.2) | 12 (30) | 8 (20) |
| lung | 3 (4.2) | 1 (2.5) | 2 (5.0) |
| brain | 9 (12.7) | 3 (7.5) | 6 (15) |
| other sites | 22 (31.0) | 11 (27.5) | 11 (27.5) |
| number of radiation site(%) | |||
| 1 | 64 | 26(81.3) | 38(97.4) |
| 2 | 5 | 4(12.5) | 1(2.6) |
| 3 | 2 | 2(6.2) | – |
| symptom of radiation site(%) | |||
| without symptom | 14 | 7(21.9) | 7(17.9) |
| pain | 12 | 11(34.4) | 12(30.8) |
| paralytic | 8 | 4(12.5) | 4(10.3) |
| others | 16 | 10(31.2) | 16(41.0) |
SD: standard deviation, UC: urothelial carcinoma.
All the cases were treated with external beam radiotherapy (EBRT), with no case in stereotactic body radiation therapy (SBRT).